You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.
The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.
The partners plan to build a database of genomic and patient-reported data to identify how genetics can impact disease outcome.
The strategy promises to offer patients the best possible predictive, preventative, and personalized care underpinned by genome sequencing.
The new "moonshot" plan, as the government refers to it, will be based on using rapid testing of nasal swabs and saliva using platforms with a turnaround time of 20 to 90 minutes.
The director of the Wellcome Trust criticizes the plan to replace Public Health England, the Guardian reports.
The Telegraph reports that the UK health secretary plans to replace Public Health England with a new health protection agency.
The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.
Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.